ストックスクリーナーアプリを入手
4.69
1.75%
0.12
前日終値:
$4.57
開ける：
$4.52
24時間の取引高:
424.91K
Relative Volume:
0.44
時価総額：
$147.23M
収益：
$160.43M
当期純損益:
$-227.64M
株価収益率:
-0.0682
EPS:
-68.77
ネットキャッシュフロー:
$-170.79M
1週間 パフォーマンス:
-7.00%
1か月 パフォーマンス:
+35.57%
6か月 パフォーマンス:
+69.71%
1年 パフォーマンス:
-72.14%
1日の値動き範囲:
$4.34
$4.685
1週間の範囲:
$4.34
$5.22
52週間の値動き範囲:
$1.38
$18.74
Agenus Inc Stock (AGEN) Company Profile
AGEN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
4.68 | 147.23M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.97 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.87 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.54 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
559.17 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.59 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | 開始されました | Robert W. Baird | Outperform |
| 2023-02-28 | 再開されました | H.C. Wainwright | Buy |
| 2022-09-28 | 開始されました | SMBC Nikko | Outperform |
| 2021-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-19 | 再開されました | B. Riley FBR | Buy |
| 2019-04-22 | 開始されました | B. Riley FBR | Buy |
| 2016-10-28 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | 繰り返されました | Maxim Group | Buy |
| 2016-03-11 | アップグレード | Maxim Group | Hold → Buy |
| 2015-12-16 | 開始されました | Jefferies | Buy |
| 2015-10-27 | ダウングレード | Maxim Group | Buy → Hold |
| 2015-07-27 | 繰り返されました | MLV & Co | Buy |
| 2015-06-11 | 開始されました | Oppenheimer | Outperform |
| 2015-01-12 | 繰り返されました | Maxim Group | Buy |
| 2015-01-09 | 繰り返されました | MLV & Co | Buy |
| 2015-01-09 | 繰り返されました | Maxim Group | Buy |
| 2014-12-19 | 繰り返されました | Maxim Group | Buy |
| 2014-05-08 | 繰り返されました | Maxim Group | Buy |
| 2014-03-14 | 繰り返されました | MLV & Co | Buy |
| 2013-10-08 | 繰り返されました | Maxim Group | Buy |
| 2012-01-05 | 開始されました | William Blair | Outperform |
| 2011-12-01 | 開始されました | Global Hunter Securities | Buy |
すべてを表示
Agenus Inc (AGEN) 最新ニュース
# Agenus and Noetik partner to develop AI-powered cancer treatment biomarkers - Investing.com India
Agenus Inc. (AGEN) Surges After Zydus Agreement, Analysts Upbeat on Stock - MSN
Agenus Partners With Noetik to Advance Biomarker Discovery for Lead Cancer Immunotherapy Combo - MarketScreener
Agenus (AGEN) and Noetik Collaborate to Enhance Cancer Treatment - GuruFocus
Agenus, Noetik Enter Research Collaboration - Nasdaq
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology | AGEN Stock News - GuruFocus
AI Breakthrough: Agenus and Noetik Join Forces to Revolutionize Cancer Patient Selection Using Virtual Cell Models - Stock Titan
10 Most Undervalued Stocks to Buy for Under $5 - Insider Monkey
Zydus Life To Buy Agenus' US Facilities For $75 Million For Entry In Biologics CDMO - MSN
Neoantigen Cancer Vaccines Industry Analysis Report 2025 with Tariff-Adjusted Forecasts and Analytics to 2030 - GlobeNewswire Inc.
Is Zydus’s Agenus Deal Opportunistic Or Strategic? - insights.citeline.com
Agenus Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - ACCESS Newswire
H.C. Wainwright Upgrades Agenus (AGEN) Stock to Buy - MSN
Agenus Announces Virtual Annual Shareholders Meeting - New Castle News
How to Join Agenus 2025 Virtual Shareholders Meeting: Complete Registration Guide - Stock Titan
Agenus climbs on deal with India’s Zydus for cancer therapy BOT/BAL - MSN
Agenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of “Hold” from Analysts - Defense World
Baird Lifts Agenus (AGEN) PT to $6, Maintains Neutral Rating - MSN
Research Analysts Issue Forecasts for Agenus FY2027 Earnings - Defense World
HC Wainwright Forecasts Agenus’ Q3 Earnings (NASDAQ:AGEN) - Defense World
Zydus Lifesciences venture capital arm to acquire stake in Agenus for USD 16 million - Medical Dialogues
Zydus enters global biologics CDMO market with $75m facility acquisitions - BioProcess International
Agenus (NASDAQ:AGEN) Upgraded to “Buy” at HC Wainwright - Defense World
Agenus (NASDAQ:AGEN) Price Target Raised to $6.00 at Robert W. Baird - Defense World
Zydus Lifesciences to acquire India, Sri Lanka rights for Agenus cancer immunotherapy BOT/BAL - Medical Dialogues
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US - 뉴스와이어
Agenus Announces Strategic Collaboration with Zydus - TipRanks
Agenus IncSigns Partnership Agreements With Zydus Lifesciences - MarketScreener
Analyst Upgrades Agenus As Zydus Deal Alleviates Cash OverhangAgenus (NASDAQ:AGEN) - Benzinga
Agenus Shares Rise After Upgrade From HC Wainwright - marketscreener.com
H.C. Wainwright upgrades Agenus stock on strategic collaboration - Investing.com Australia
H.C. Wainwright upgrades Agenus stock on strategic collaboration By Investing.com - Investing.com South Africa
Wall Street Analysts Believe Agenus (AGEN) Could Rally 26.6%: Here's is How to Trade - Yahoo Finance
Agenus (AGEN) Price Target Raised by Baird as Neutral Rating Mai - GuruFocus
Agenus (AGEN) Price Target Raised by Baird as Neutral Rating Maintained | AGEN Stock News - GuruFocus
Agenus (AGEN) Upgraded to 'Buy' by HC Wainwright & Co. | AGEN St - GuruFocus
HC Wainwright & Co. Upgrades Agenus (AGEN) - Nasdaq
Agenus (AGEN) Stock Price Target Increased by Baird | AGEN Stock News - GuruFocus
Agenus and Zydus sign agreements for botensilimab and balstilimab - Yahoo Finance
Zydus gets rights for next gen I-O platforms from Agenus - The Pharma Letter
HC Wainwright Upgrades Agenus to Buy From Neutral, $25 Price Target - marketscreener.com
Agenus (AGEN) Boosted to Buy Following Key Zydus Partnership | A - GuruFocus
Agenus (AGEN) Boosted to Buy Following Key Zydus Partnership | AGEN Stock News - GuruFocus
Zydus signs deal with Agenus for next-gen cancer immunotherapies - Healthcare Radius
Zydus to enter global biologics CDMO business to accelerate development of innovative therapies - Pharmabiz.com
Jane Street Group LLC Raises Stock Position in Agenus Inc. (NASDAQ:AGEN) - Defense World
Zydus to enter global biologics CDMO business Plans to acquire Agenus’ U.S. manufacturing facilitiesto accelerate development of innovative therapies - APN News
Zydus to acquire Agenus’ US manufacturing facilities, forays into global biologics CDMO business - Indian Pharma Post
Zydus Lifesciences acquires Agenus Biologics facilities in US, enters global CDMO market - Express Pharma
Zydus to enter global biologics CDMO business: Plans to acquire Agenus' U.S. manufacturing facilities to accelerate development of innovative therapies - StreetInsider
Agenus inks $141M deal with Zydus for cancer drugs, facilities By Investing.com - Investing.com South Africa
Agenus Inc (AGEN) 財務データ
収益
当期純利益
現金流量
EPS
1.46%
0.39%
大文字化:
|
ボリューム (24 時間):